Advanced Search

Ophthalmic Oncology Evaluations

To view Evaluated Articles, you must have an active subscription (or trial) and be signed in.
If you have an active subscription (or trial), please sign in. If your access has expired, you can subscribe at $9.95 per month. If you think you should be able to access this content, please contact us.

Sign in | Free Trial | Subscribe | Recommend to Library

New to F1000? See the Top Rated article below for a free preview of one of our Evaluated Articles.

SECTION HEADS

  • Photo of David H Abramson

    David H Abramson

    Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

  • Photo of J William Harbour

    J William Harbour

    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO, USA

Section Topics

  • » Conjunctival tumors
  • » Lid tumors
  • » Miscellaneous intraocular tumors
  • » Orbital tumors
  • » Retinoblastoma
  • » Uveal melanoma

TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]

6
Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma.

Bronkhorst IH, Maat W, Jordanova ES, Kroes WG, Schalij-Delfos NE, Luyten GP, Jager MJ. Arch Pathol Lab Med. 2011 Aug; 135(8):1042-7

1 Evaluation, most recent by

Arun D Singh and Mary Beth Aronow, Cleveland Clinic Foundation, USA. F1000 Ophthalmology

INDIVIDUALS

Get instant access to evaluations from over 10,000 experts in biology and medicine by taking a free trial or an individual subscription.

Get a FREE Trial Subscribe for $9.95 per month

Already have a subscription? Sign in for instant access. If you are signed in but are not able to view content, your access has expired. Please take out a subscription or recommend F1000 to your librarian.

RECOMMENDATIONS

Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.

Recommend to your Librarian

LIBRARIANS & INFORMATION MANAGERS

Get an extended free trial supporting clinicians and researchers at your academic or corporate institution.

Request an Institutional Trial

FREE ACCESS

Your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.